Literature DB >> 23600477

Targeting ubiquilin-1 in Alzheimer's disease.

Mari Takalo1, Annakaisa Haapasalo, Teemu Natunen, Jayashree Viswanathan, Kaisa Ma Kurkinen, Rudolph E Tanzi, Hilkka Soininen, Mikko Hiltunen.   

Abstract

INTRODUCTION: Alzheimer's disease (AD) is a common neurodegenerative disorder affecting an increasing number of people worldwide as the population ages. Currently, there are no drugs available that could prevent AD pathogenesis or slow down its progression. Increasing evidence links ubiquilin-1, an ubiquitin-like protein, into the pathogenic mechanisms of AD and other neurodegenerative diseases. Ubiquilin-1 has been shown to play a key role in the regulation of the levels, subcellular targeting, aggregation and degradation of various neurodegenerative disease-associated proteins. These include the amyloid precursor protein and presenilins that are intimately involved in the mechanisms of AD. AREAS COVERED: Here, the properties and diverse functions of ubiquilin-1 protein in the context of the pathogenesis of AD and other neurodegenerative disorders are discussed. This review recapitulates the available knowledge on the involvement of ubiquilin-1 in the genetic and molecular mechanisms in AD. Furthermore, the association of ubiquilin-1 with specific proteins and mechanisms involved in the pathogenesis of neurodegenerative diseases is described and the known ubiquilin-1-interacting proteins summarized. EXPERT OPINION: The variety of ubiquilin-1-interacting proteins and its central role in the regulation of protein levels and degradation provides a number of novel candidates and approaches for future research and drug discovery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23600477     DOI: 10.1517/14728222.2013.791284

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  6 in total

Review 1.  The impact of proteostasis dysfunction secondary to environmental and genetic causes on neurodegenerative diseases progression and potential therapeutic intervention.

Authors:  Abdelmagid M Elmatboly; Ahmed M Sherif; Dalia A Deeb; Amira Benmelouka; May N Bin-Jumah; Lotfi Aleya; Mohamed M Abdel-Daim
Journal:  Environ Sci Pollut Res Int       Date:  2020-02-19       Impact factor: 4.223

2.  Platelet-rich plasma promotes peripheral nerve regeneration after sciatic nerve injury.

Authors:  Su-Long Wang; Xi-Lin Liu; Zhi-Chen Kang; Yue-Shu Wang
Journal:  Neural Regen Res       Date:  2023-02       Impact factor: 6.058

3.  Ubiquilin 1 Promotes IFN-γ-Induced Xenophagy of Mycobacterium tuberculosis.

Authors:  Erik T Sakowski; Stefan Koster; Cynthia Portal Celhay; Heidi S Park; Elina Shrestha; Stefanie E Hetzenecker; Katie Maurer; Ken Cadwell; Jennifer A Philips
Journal:  PLoS Pathog       Date:  2015-07-30       Impact factor: 6.823

Review 4.  The ubiquitin proteasomal system: a potential target for the management of Alzheimer's disease.

Authors:  Kundlik Gadhave; Nityanand Bolshette; Ashutosh Ahire; Rohit Pardeshi; Krishan Thakur; Cristiana Trandafir; Alexandru Istrate; Sahabuddin Ahmed; Mangala Lahkar; Dafin F Muresanu; Maria Balea
Journal:  J Cell Mol Med       Date:  2016-03-29       Impact factor: 5.310

5.  The MT-CO1 V83I Polymorphism is a Risk Factor for Primary Open-Angle Glaucoma in African American Men.

Authors:  David W Collins; Harini V Gudiseva; Venkata R M Chavali; Benjamin Trachtman; Meera Ramakrishnan; William T Merritt; Maxwell Pistilli; Rebecca A Rossi; Stephanie Blachon; Prithvi S Sankar; Eydie Miller-Ellis; Amanda Lehman; Victoria Addis; Joan M O'Brien
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-04-01       Impact factor: 4.799

6.  Decreased expression of ubiquilin‑1 following neonatal hypoxia‑ischemic brain injury in mice.

Authors:  Li Luo; Yilin Liu; Xing Tu; Xuxin Ren; Wenyan Zhao; Jing Liu; Li Zhang; Weiqiang Chen; Pei Zhang; Weicai Wang; Lanhai Lü; Mengxia Wang
Journal:  Mol Med Rep       Date:  2019-04-15       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.